Corrigendum to “Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models” [Bioorg. Med. Chem. Lett. 21 (2011) 463]